Related Experiment Video
Updated: Aug 5, 2026

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
Prognostic value of soluble intercellular adhesion molecule-1 (s-ICAM-1) in HIV-infected children
E Gaddi1, S Laucella, J Balbaryski
1División Inmunología, Hospital Dr Pedro de Elizalde, Buenos Aires, Argentina. vgiradi@intramed.net.ar
Insights
Soluble intercellular adhesion molecule-1 (s-ICAM-1) is elevated in children with human immunodeficiency virus (HIV) infection, correlating with disease severity. s-ICAM-1 levels may serve as a biomarker for monitoring HIV progression in pediatric patients.
Area of Science:
- Immunology
- Virology
- Pediatrics
Background:
- Cell adhesion molecules are crucial regulators of host defense and immune responses.
- Human immunodeficiency virus (HIV) infection impacts the immune system, necessitating biomarkers for disease monitoring.
Purpose of the Study:
- To investigate the levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) in children with HIV infection.
- To assess the correlation of s-ICAM-1 levels with disease severity, clinical status, and other immune markers.
Main Methods:
- Sera from HIV-infected children (categorized by disease severity), seroreverting children, and healthy controls were analyzed for s-ICAM-1.
- Levels of s-ICAM-1 were compared across groups.
- Correlations with beta 2 microglobulin (beta 2m), immunoglobulin A (IgA), and CD4(+) T-cell counts were examined.
Main Results:
- Significantly increased s-ICAM-1 levels were observed in HIV-infected children compared to seroreverting children and healthy controls.
- Higher s-ICAM-1 levels were associated with more severe HIV infection.
- s-ICAM-1 levels correlated positively with beta 2m and IgA, and negatively with CD4(+) T-cell counts.
- s-ICAM-1 levels fluctuated with changes in clinical condition, increasing with disease progression and decreasing with improvement.
Conclusions:
- Soluble intercellular adhesion molecule-1 (s-ICAM-1) is a potential biomarker for evaluating disease progression in pediatric HIV infection.
- Monitoring s-ICAM-1 may aid in assessing clinical status and treatment response in children with HIV.
Abstract:
Central events in the host defence system and immune-mediated damage are tightly regulated by cell adhesion molecules. Sera from 28 human immunodeficiency virus (HIV)-1 infected children divided into groups according to disease severity, six seroreverting (SR) children and 25 healthy controls were studied to detect the presence of soluble intercellular adhesion molecule-1 (s-ICAM-1). Soluble ICAM-1 levels were found to be significantly increased in HIV-infected children in comparison with SR children or healthy controls. Levels of soluble ICAM-1 were higher in patients with severe forms of HIV-infection than in those with a milder form of the disease. Significant differences in titers of s-ICAM-1 were recorded between SR children and HIV-infected children with mild disease or healthy controls. There was a significant correlation between s-ICAM-1 levels and the concentrations of beta 2 microglobulin (beta 2m) and, to a lesser extend, immunoglobulin A levels (IgA). Soluble ICAM-1 levels didn't change considerably in HIV-infected children in stable clinical conditions, independently of their clinical stage of the disease, during a follow-up period of 9-12 months. Conversely, s-ICAM-1 levels increased simultaneously with the appearance of new well-defined clinical disorders or decreased during the improvement of clinical conditions. A significant negative correlation was recorded between the titers of the s-ICAM-1 and the CD4(+) T-cell levels. These results suggest that the s-ICAM-1 might be another useful tool to evaluate disease progression.
More Related Videos
13:13Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques
Published on: September 25, 2018
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020